CN85102334A - 制备二氢吡啶制剂的方法 - Google Patents
制备二氢吡啶制剂的方法 Download PDFInfo
- Publication number
- CN85102334A CN85102334A CN198585102334A CN85102334A CN85102334A CN 85102334 A CN85102334 A CN 85102334A CN 198585102334 A CN198585102334 A CN 198585102334A CN 85102334 A CN85102334 A CN 85102334A CN 85102334 A CN85102334 A CN 85102334A
- Authority
- CN
- China
- Prior art keywords
- preparation
- dihydropyridine
- parts
- weight
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000945 filler Substances 0.000 claims abstract description 13
- -1 N-methyl-N-benzyl amino Chemical group 0.000 claims abstract description 11
- 239000007787 solid Substances 0.000 claims abstract description 9
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims description 24
- 239000001913 cellulose Substances 0.000 claims description 13
- 229920002678 cellulose Polymers 0.000 claims description 13
- 235000010980 cellulose Nutrition 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 10
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- 229960005425 nitrendipine Drugs 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 235000004213 low-fat Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000227 nisoldipine Drugs 0.000 claims description 3
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229960000715 nimodipine Drugs 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 229920002261 Corn starch Polymers 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 239000004744 fabric Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 4
- 239000004368 Modified starch Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000019426 modified starch Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 235000011837 pasties Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 2
- 244000173166 Pyrus ussuriensis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102100026038 Lens fiber membrane intrinsic protein Human genes 0.000 description 1
- 101710115990 Lens fiber membrane intrinsic protein Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Abstract
本发明涉及具有改善生物利用率的新型固体二氢吡啶制剂,其中含有1份(重量)式I的微溶二氢吡啶和1.0至20份(重量)易溶于水的填料,优选2至15份,如必要,可加其他一般的助剂和赋形剂。式I中,R1是由C2—C3烷氧基选择取代的C1—C4烷基,R2是由C1—C3烷氧基选择取代的C1—C10烷基,三氟甲基或N-甲基-N-苄氨基;R3为C1—C4烷基,氰基或羟甲基;X为2-或3-硝基,2,3-二氯或在2,3位上含有=N-O-N=的环。
Description
本发明关于固体状的新型二氢吡啶制剂,具有改善生物利用率,其中包含微溶二氢吡啶和易溶填料,以及制剂的制备方法和作为药剂的应用,特别是作为静脉和血压剂的应用。
二氢吡啶用在(血液)循环上特别有效,这一点已经公开(见英国专利1358951),由于许多二氢吡啶的溶解性极其微弱,因此,在医学领域的药物制备上出现了很多困难,从许多出版物和专利申请书有关这些活性化合物特殊配比的叙述来看,困难是明显,象这样的如,英国专利1,456,618一固体医疗制的描述和权利要求,同样地叙述了保证微溶二氢吡啶良好的生物利用率,然而,DT-OS(德国公开说明书),2822882描述了固体配料的组成,其中叙述了活性化合物的溶微性是利用一定量的加溶剂和表面活性物质来补偿的,此外,欧洲公开说明书1247中谈到利用聚乙二醇和一定的多孔载体来改善的二氢吡啶的吸收能力。
同样,改善生物利用率的各种各样的方法与改善溶解性是直接联系的,这些已在文献中描述过了,除改变化学结构,如靠取代基的结合来改善溶解性外,大量的有关改变活性化合物物理特性的方法,已经有所描述,象这样的如,活性化合物颗粒尺寸的减小,晶体结构的改变,成盐形式的制备,湿润剂的添加,利用与其它物质的复合,生物载体的利用,固态色散体(共沉淀物)的产生以及已提出的表面吸附剂的制备,(见S.H.Yalkowskay药和药物科学,12,135-180(1981)和J.Polderman,Formulation and preparationof dosage forms,Elsevier/North-Holland Biomedicalp ress,1977,215-219)
用所有特殊的措施来补偿溶解性极差的二氢吡啶的尝试已过时,同时,对于保证良好的生物利用率有一定的不利条件,利用表面活性剂加溶剂和一定的载体,它们都有一个特殊的表面,例如是多孔的,经常导致制剂的给药形状不符合需要的大小。为了易于吞咽,片状或胶囊这种型号常常变为专一的形式,例如,椭球形或者椭园形的,但当制剂重量大于40mg时总还不能产生令人满意的结果,而且也没有常用的为制备小制剂所提供的某种适当的溶液。
本发明是关于固体二氢吡啶制剂,具有改善生物利用率,其中包含通式为Ⅰ的微溶二氢吡啶的重量份为1份。
其中:R1表示C1-C4的烷基,可取代或不取代C2-C3的烷氧基
R2表示C1-C10的烷基,可取代或不取代C1-C3的烷氧基,三氟甲基或N-甲基-N-苄胺基
R3表示被C1-C4的烷基,氰基或羟甲基,X表示2位或3位的硝基,2,3-二氯或一个含有=N-O-N=结构的与2,3位相连的环,制剂还含有溶于水的填料,其重量份数为1至20,最好取2至15,在适当场合还加入一些常用的助剂和赋形剂。
根据本发明,特别值得注意的是二氢吡啶制剂的添加剂,如易溶于水的填料,糖和/或糖醇,象这样的如。乳糖,蔗糖,果糖,葡萄糖,甘露糖醇和山梨(糖)醇,和/或易溶于水的盐,如,镁盐,钙盐,钾盐,钠盐和铵盐,也可能是以阴离子存在的盐,如氯化物,碳酸盐,柠檬酸盐,酒石酸盐,乳酸盐,乙酸盐和碳酸氢盐。
根据本发明,其二氢吡啶制剂,其中最好选择包含通式Ⅰ重量份数为1份的二氢吡啶。其中,R1和R2总是互不相同的,特别在nisoldipine,nimodipine或nitrenelipine中,其易溶填料的重量份数为2至15份,特别要用乳糖和/甘露糖醇。
就溶于水的填料来说应该是生理可以接受的物质,它们的溶解性至少是每100mg水溶解15g,在25℃时,至少是每100mg水溶解20g。
根据本发明被制成颗粒状的化合物制剂,是由二氢吡啶活性化合物和易溶于水填料一起通过潮湿颗粒加工或经干燥压制成型为最终的颗粒,在那里,至少要适当的加入一种压片助剂,以形成药片。
根据本发明所用的二氢吡啶,最好选择通式Ⅱ的叉化合物和通式Ⅲ烯胺化合物反应而制得。
R1,R2,R3和X正如通式Ⅰ表明的,在低脂肪醇作为溶剂存在时,温度在40至100℃。
这个反应优点在于:使用低摩尔浓度的通式Ⅲ烯胺化合物和除去反应生成的水,在反应期间,适当的用恒沸点蒸馏。
制备通式为Ⅱ的化合物,最好选择在低脂肪醇作溶剂时,一定摩尔量的醋羧酸酯和芳香醛反应,特别是醇要具有1至4有碳原子,同时在一定量的催化剂杂氮环己烷醋酸盐的存在下,温度在20至70℃之间。
制备通式Ⅲ的烯胺化合物是由酮羧酸酯和氨在低脂肪醇存在下进行反应,最好选用异丙醇,温度在0至50℃之间。
所提及的助剂和赋形剂的例子为:分解促进剂,如淀粉,改性淀粉,纤维素,纤维素衍生物,交联聚乙烯吡咯烷酮(PVPP),藻酸钠和固体硅胶;粘合剂如明胶,黄蓍胶,葡萄糖浆,淀粉浆糊,聚乙烯吡咯烷酮(PVP),纤维素衍生物,聚乙烯乙二醇,分子量1000-5000(PEG)和藻酸盐;润滑剂如硬脂酸镁,硬脂酸钙,硬脂酸,石蜡,滑石,植物脂肪或动物脂肪,油和蜡,聚乙烯吡咯烷酮,分子量,1000-5000以及硅酮。硫酸钙,碳酸钙,磷酸二氢钙和磷酸三氢钙,碳酸镁,碱式碳酸镁,氯化钠,柠檬酸钠和柠檬酸钾,酒石酸盐,丁二酸盐,淀粉,改性淀粉,纤维素,粉状纤维素;糖类,如乳糖,蔗糖,葡萄糖和糖醇,如甘露糖醇和山梨(糖)醇。
特别值得注意的是添加助剂,赋形剂和填料中所包含的组份如,淀粉,改性淀粉,如糊状淀粉,纤维素,聚乙烯吡啶烷酮,交联聚乙烯吡咯烷酮,胶体硅胶,蔗糖,碱式碳酸镁,硬脂酸镁和硬脂酸钙箭等。
对现有技术的叙述,本发明是极其令人惊奇的,由二氢吡啶和上述填料这一一起制成的微溶二氢吡啶颗粒在释放过程中可以取得有效的增加,同时在生物利用率上得到了重大的改进是有可能的。根据文章的叙述,取得这样的效果不依赖于附加助剂的存在,其增加释放率而取决了,如,络合物,表面活性物质和水溶聚合物等成份。
上述的微溶二氢吡啶是指每升至多能溶20mg的二氢吡啶,温度在25℃。
利用美国搅拌用的浆形棒,在下条件下进行释放试验:
0.1NHCL400ml
搅拌速度每分钟100转
根据本发明的制剂(例1的产品),两小时后,制剂到了约80%的nitrendipine的释放率。与传统的nitrendipine小片的公式叙述相符,其中用的nitrendipine是同样的晶状组合物,其中包括同样的助剂,2小时后显示出来的释放率仅约40%。从表格1可知释放的改进是明显的。
表1
含有nitrendipine小片的vitro释放:(用美国浆形棒搅拌法)。以nitrendipine的累积释放作为使用剂量的百分数。
小片 小片
释放时间(小时) 例1 对比例
0.25 29 12
0.5 56 21
1 69 34
2 84 41
对比实例
100g nitrendipine,玉米淀粉910g,粉状纤维素680g,550g碳酸钙和10g十二烷基磺酸钠在行星齿轮混合器中混合5分钟,然后把含水的二氢吡啶溶液(固体含量50g)制成颗粒,时间10分钟。使湿的组合物透过一个筛网,然后在流化床干燥器中干燥,使之最终含水量约为4.5%。被干燥的颗粒通过筛网被均匀的制成(筛网孔尺寸0.8mm),并与50g硬脂酸镁进行强有力的混合,然后,颗粒被压制成片成,片剂含量为235mg。
实施例
例1
100g nitrendipine,1200g乳糖,1280g改性淀粉,430g粉状纤维素,350g碳酸钙和10g十二烷基磺酸钠在行星齿轮混合器中混合5分钟,然后把含水的二氢吡啶溶液(固体含量50g)制成颗粒,时间10分钟。使湿组合物通过筛网然后在流化床干燥器中干燥,使之最终含水量约为4.5%。干燥的颗粒通过筛网(0.8mm孔径尺寸)而均匀制成并与50g硬脂酸镁的强有力的混合,把颗粒压制成片剂,片剂重量为235g。片剂能被保健硝基纤维素复盖。
例2
50g nitrendipine,2216g甘露糖醇,2244g玉米淀粉,250g已预先变为糊状物的淀粉和750G粉状纤维素利用Tween80的水溶液(含量15g),在混合颗粒成粒器中使之制成颗粒。然后,湿组合物通过粗锉(穿孔尺寸4mm),然后干燥到剩余物的湿含量约3.8%,在循环空气干燥炉中,干燥颗粒通过筛网(网孔尺寸1.25mm)被均匀制成并与15g硬脂酸镁强有力的混和,然后压制成片剂,片剂重量277mg。
小片能被防光的保健涂层复盖。或者,颗粒能被填装成胶囊。
例3
1200g甘露糖醇,400g nitrendipine100g粉状纤维素,1800g玉米淀粉和40g十二烷基磺酸钠,在混合颗粒成粒器(例如Lodige MGT30)中混合1分钟,然后,在转子转速为每分钟200转的颗粒成粒器中,利用糊状淀粉(淀粉含量200g)使之形成颗粒,时间为5分钟。借助切碎装置Ⅱ,获得了平均约为200至300微米尺寸的颗粒。颗粒通过粗锉(穿孔2.0mm),然后在流化床干燥器(例如Glatt WST5)中干燥至最终含水量约4.0%,被干燥的颗粒借助于硬脂酸镁在混合器中使之混合,时间10分钟,然后压缩成平均直径为9mm,重量约237mg的小片。
形成的小片能另外的被不透明包衣复盖,其中包含如,红色氧化铁作为光的保护层。
例4
600g乳糖,200g nimoelipine,800g粉状纤维素,600g玉米淀粉,25g Tween80和50g硬脂酸镁在立方体混会器中使之混合,然后干燥压制(胶凝工作压力50下进行轧制,压实压力为35巴)。借助于1.25mm的筛网并与25g硬脂酸镁和200g玉米淀粉混合物碾碎混和,而均匀制成。最终颗粒被压制成片剂,片剂重量为250mg直径为9mm。
形成的小片能直接地使用,另外加入含有羟丙基甲基纤维素,聚氧乙烯和氧化铁的防药胶膜或其它生理上能接受的颜料。
例5
950g甘露糖醇,300g nisoldipine,1255g玉米淀粉,150g已预先转变成糊状的玉米淀粉,900g粉状纤维素在行星齿轮混合器中(collette MP20)中混合8分钟,在连续加入250mg,强度为2.0%的十二烷基磺酸钠的不透明溶液后,利用混合器转速的增加使之制成颗粒,时间5分钟,湿组合物被粗擦,在流化床干燥器中干燥至最湿含量约3.8%。然后借助于通过筛网(网孔尺寸1.0mm)制成一样的尺寸,利用75g硬脂酸镁混和后,获得了最混合物,压制成片型,小片含量为247mg。
另外,最后得到的小片可被包衣包住,包衣是不透光的。或者,颗粒可填装入硬胶胶囊。
Claims (9)
1、制备一类具有改善生物利用率的固体二氢吡啶制剂的方法,其特征在于通式Ⅰ的微溶二氢吡啶
其中,R1表示C1-C4的烷基,可取代或不取代C2-C3的烷氧基;
R2表示C1-C10的烷基,可取代或不取代C1-C3的烷氧基,三氟甲基或N-甲基-N-苄胺基;
R3表示C1-C4的烷基,氰基或羟甲基;
X表示2-或3-硝基,2,3-二氯或一个含有=N-O-N=的与2,3位相连的环,
是由通式Ⅱ的烯内鎓盐化合物,
其中R1和X正如上述定义的相同,与通式Ⅲ的烯胺化合物反应,
其中R2和R3正如上述所定义的相同,
并在碳原子数为1至4的低脂肪醇存在下以及温度在40和100℃之间反应制得的;利用重量份数为1至20份的易溶于水的助剂使上述化合物变为通式Ⅰ的重量份数为1份的化合物,在适当的场合下可加入一些其它常用的助剂和赋形剂,制备成一种具有改善生物利用率的制剂。
2、根据权利要求1所述制备二氢吡啶制剂的方法,其特征在于含有易溶于水的填料,从组成讲要含有乳糖和甘露糖醇。
3、根据权利要求1所述制备通式为Ⅰ的二氢吡啶制剂的方法,其特征在于R1和R2总是互不相同的。
4、根据权利要求1至3所述制备二氢吡啶制剂的方法,其特征在于含有微溶二氧吡啶的重量份数为1份,和重量份数为2至15份的易溶于水的填料。
5、根据权利要求1至4所述制备二氢吡啶制剂的方法,其特征在于含有Nitrendipine,nisoldipine或nimodipine。
6、根据权利要求1至5制备制剂的方法,其特征在于制剂是颗粒状的。
7、根据权利要求1所述制备制剂的方法,其特征在于:重量份数为1份的通式为I的微溶二氢吡啶和重量份数为1至20份的易溶填料,与助剂和赋形剂一起制成颗粒,在适当的场合这些颗粒还可进一步压制成常用的给药形式。
8、根据权利要求7的制备方法,其特征在于:给出的重量份数为1份的二氢吡啶和重量份数为2至15份的易溶于水的填料,并和淀粉,纤维素,聚乙烯吡咯烷酮和二氧化硅一起在颗粒形成器中形成水状颗粒,最后所得的颗粒同样地转变成常用的给药形式。
9、根据权利要求1所述的二氢吡啶制剂,可应用于调节(血液)循环失调。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19843419128 DE3419128A1 (de) | 1984-05-23 | 1984-05-23 | Dihydropyridinpraeparate und verfahren zu ihrer herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
CN85102334A true CN85102334A (zh) | 1987-01-24 |
Family
ID=6236594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN198585102334A Pending CN85102334A (zh) | 1984-05-23 | 1985-04-01 | 制备二氢吡啶制剂的方法 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0164588A3 (zh) |
JP (1) | JPS60255737A (zh) |
KR (1) | KR850008281A (zh) |
CN (1) | CN85102334A (zh) |
AU (1) | AU4280985A (zh) |
DD (1) | DD235183A5 (zh) |
DE (1) | DE3419128A1 (zh) |
DK (1) | DK228285A (zh) |
ES (1) | ES8607015A1 (zh) |
GR (1) | GR851247B (zh) |
HU (1) | HUT38251A (zh) |
IL (1) | IL75242A0 (zh) |
PT (1) | PT80498B (zh) |
ZA (1) | ZA853874B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105168175A (zh) * | 2015-08-25 | 2015-12-23 | 瑞阳制药有限公司 | 尼索地平胶囊及其制备方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3419131A1 (de) * | 1984-05-23 | 1985-11-28 | Bayer Ag, 5090 Leverkusen | Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung |
US4940556A (en) * | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
US5198226A (en) * | 1986-01-30 | 1993-03-30 | Syntex (U.S.A.) Inc. | Long acting nicardipine hydrochloride formulation |
JPS6396126A (ja) * | 1986-10-13 | 1988-04-27 | Taisho Pharmaceut Co Ltd | 安定化組成物 |
ES2043719T3 (es) * | 1987-06-12 | 1994-01-01 | American Cyanamid Co | Administracion de farmacos por via percutanea. |
US5114946A (en) * | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
NO883326L (no) * | 1987-08-11 | 1989-02-13 | Bayer Ag | Dhp-retard-tilberedning. |
US5091191A (en) * | 1988-02-03 | 1992-02-25 | Yoshitomi Pharmaceutical Industries, Ltd. | Pharmaceutical composition with improved dissolution property |
HU200926B (en) * | 1988-10-28 | 1990-09-28 | Egyt Gyogyszervegyeszeti Gyar | Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules |
JPH09208458A (ja) * | 1996-02-02 | 1997-08-12 | Ss Pharmaceut Co Ltd | 不快な味がマスキングされた製剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2117571C3 (de) * | 1971-04-10 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
DE2400819C2 (de) * | 1974-01-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung |
GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
EP0001247A1 (en) * | 1977-09-14 | 1979-04-04 | Kanebo, Ltd. | Pharmaceutical preparation containing nifedipine and a method for producing the same. |
FI72874B (fi) * | 1983-04-12 | 1987-04-30 | Orion Yhtymae Oy | Foerfarande foer framstaellning av laett absorberbar oral doseringsform av laekemedel av nifedipin. |
-
1984
- 1984-05-23 DE DE19843419128 patent/DE3419128A1/de active Pending
-
1985
- 1985-04-01 CN CN198585102334A patent/CN85102334A/zh active Pending
- 1985-05-11 EP EP85105798A patent/EP0164588A3/de not_active Withdrawn
- 1985-05-20 IL IL75242A patent/IL75242A0/xx unknown
- 1985-05-20 JP JP60106215A patent/JPS60255737A/ja active Pending
- 1985-05-21 DD DD85276557A patent/DD235183A5/de unknown
- 1985-05-21 ES ES543349A patent/ES8607015A1/es not_active Expired
- 1985-05-21 GR GR851247A patent/GR851247B/el unknown
- 1985-05-21 PT PT80498A patent/PT80498B/pt unknown
- 1985-05-22 KR KR1019850003503A patent/KR850008281A/ko not_active Application Discontinuation
- 1985-05-22 ZA ZA853874A patent/ZA853874B/xx unknown
- 1985-05-22 DK DK228285A patent/DK228285A/da not_active Application Discontinuation
- 1985-05-23 AU AU42809/85A patent/AU4280985A/en not_active Abandoned
- 1985-05-23 HU HU851958A patent/HUT38251A/hu unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105168175A (zh) * | 2015-08-25 | 2015-12-23 | 瑞阳制药有限公司 | 尼索地平胶囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
DK228285D0 (da) | 1985-05-22 |
ES543349A0 (es) | 1986-06-01 |
JPS60255737A (ja) | 1985-12-17 |
PT80498A (en) | 1985-06-01 |
EP0164588A2 (de) | 1985-12-18 |
KR850008281A (ko) | 1985-12-16 |
GR851247B (zh) | 1985-11-25 |
IL75242A0 (en) | 1985-09-29 |
ES8607015A1 (es) | 1986-06-01 |
DE3419128A1 (de) | 1985-11-28 |
DK228285A (da) | 1985-11-24 |
AU4280985A (en) | 1985-11-28 |
DD235183A5 (de) | 1986-04-30 |
ZA853874B (en) | 1986-01-29 |
EP0164588A3 (de) | 1986-03-19 |
PT80498B (en) | 1987-04-21 |
HUT38251A (en) | 1986-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE1000130A4 (fr) | Sels pharmaceutiques d'amlodipine ameliores et compositions pharmaceutiques les contenant. | |
EP0257369B1 (en) | Improved estradiol implant composition and method for preparation | |
EP0235986B1 (en) | Slow release formulation | |
US4254099A (en) | Pharmaceutical tablet composition | |
CN85102334A (zh) | 制备二氢吡啶制剂的方法 | |
US4150110A (en) | Coated granules of polyacrylic alkali metal salts and method of producing same | |
JPS6147807B2 (zh) | ||
JPH026332B2 (zh) | ||
CN86106839A (zh) | 含有维生素的颗粒及其制备方法 | |
EP0001247A1 (en) | Pharmaceutical preparation containing nifedipine and a method for producing the same. | |
PL155652B1 (en) | Method for manufacturing ion exchange resins containing derivatives of quinolon carboxylic acid | |
HU204694B (en) | Process for producing granulated pharmacetuical compositions comprising captopril | |
RU96100835A (ru) | Способ получения флавано-лигнановых композиций с улучшенными высвобождением и всасываемостью, композиции, получаемые этим способом, содержащее их лекарственное средство и способ его получения | |
US5089276A (en) | Calcium pantothenate composite | |
FR2661610A1 (fr) | Nouvelle forme lyophilisee de la diosmine et sa preparation. | |
CN85101697A (zh) | 二氢吡啶化合制剂及其制备方法 | |
JPH029007B2 (zh) | ||
EP0063884B1 (en) | Oxazole derivatives, their preparation and use | |
JPS60255736A (ja) | ニフエジピン調製物 | |
EP0223033B1 (de) | Verfahren zum gleichzeitigen Trocknen und Granulieren von Extraktstoffen aus enteiweisstem Kälberblut, nach diesem Verfahren erhaltenes Granulat und dessen Verwendung zur Herstellung von pharmazeutischen Präparaten | |
AU681980B2 (en) | Preparation of fusidic acid tablets | |
CN85101820A (zh) | 制备一种硝苯吡啶复合制剂的方法 | |
RU2171673C1 (ru) | Фармацевтическая композиция и способ ее получения | |
DE3304864A1 (de) | Adsorbate von prostaglandinen | |
CN86103062A (zh) | 缓放性制剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |